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Obstruction to the circulation has catastrophic consequences.
On the high-flow arterial side acknowledged risk factors
include dyslipidaemia, smoking, poorly controlled
hypertension and renal disease. Additionally, venous
thrombosis correlates with obesity, hormonal imbalance and
reduced mobility especially when this is combined with
dehydration, for example in long-distance air travel.
Superimposed upon such environmental predictors of
hypercoagulability is an impressively expanding list of genetic
determinants that impair functional integrity of intimal cells,
and this happens irrespective of anatomical site. Among these
are reduced levels of antithrombin III, protein C or S and
mutations in factor II or V, with the latter giving rise to
resistance in protective effects of activated protein C.
Furthermore there is an increasing awareness of the adverse
effects that follow sustained elevation in plasma homocysteine
levels. This may be hereditary and so explain the familial
occurrence of premature vascular disease whether in the
cerebral, coronary or peripheral circulations, but an abundance
of data document the comparable hazard that is acquired with
renal or hepatic failure or with use of many drugs.1 Neither
should it be overlooked that such predisposing factors can
occur together with compelling data that appropriate doses of
folic acid and vitamins B12 and B6 can return the
hyperhomocysteinaemia to normal.2 The relevant issue is what
role needs to be assigned to such intervention in primary as
opposed to secondary prevention.3
Physiology
Physiologically the huge intimal area presents a non-
thrombogenic and antiadhesive surface to the blood. 4
Protective molecules include prostacyclin and natriuretic
peptide that are opposed by the endothelins and thromboxane
A2.
4 The secretion of these active mediators plays a key role in
coagulation as well as modulating immune response and
contributing to vascular tone.
Pathophysiology
Pathophysiologically it is seen that homocysteine inflicts its
damage by directly disrupting this barrier in a dose and time-
dependent manner, doing so incrementally even within the
normal range. The injury results from generation of active
radicals, reduction in  nitric oxide and increase in adhesion
proteins that enhance platelet aggregation. Such a changing
phenotype shifts the balance to coagulation through release of
tissue plasminogen activator, impairment of thrombomodulin
and diminished generation of the naturally occurring
anticoagulant protein C.4
Molecular level
At molecular level raised plasma concentration reflects, most
typically, genetically determined decreases in cystathionine b-
synthase, mutation in thermolabile variant of
methylenetetrahydrofolate reductase or methionine synthase
deficiency. Acquired causes range from increasing age and
menopause, through lifestyle where tobacco and coffee have
been incriminated to deficiencies of cobalamin, pyridoxine and
folic acid. Additionally, similar elevations occur in hepatic
impairment, renal dysfunction, systemic lupus erythematosus
and a number of malignancies as well as solid organ
transplantation.1 Of particular note is a wide range of drugs in
regular use exemplified by methotrexate, phenytoin,
azathioprine, theophylline, metformin, thiazide diuretics,
colestipol, nicotinic acid and oral contraceptives.1
Treatment
Treatment rests on appreciating that this amino acid is
constantly generated from methionine. It is then disposed of by
remethylation dependent upon an adequate supply of folate
and maintenance of normal activity for the specific synthase
requiring vitamin B12 as the co-factor. There is an alternative
pathway in the liver where the methyl donor is betaine and
this requires the presence of a specific transferase. Clearance of
the offending molecule from the plasma also takes place by
transsulphuration requiring vitamin B6.
3
191
March 2003, Vol. 93, No. 3  SAMJ
Homocysteine and the vascular endothelium
Peter Jacobs, Lucille Wood
GREAT DEBATE
Peter Jacobs is a consultant physician and clinical haematologist
with research interests in leukaemia, lymphoma and myeloma. An
additional area of investigation is pathophysiology of disordered
haemostasis.
Lucille Wood co-ordinates all accredited departmental
management protocols, having special established involvement in
the use of matched unrelated donors for allogeneic haematopoietic
stem cell transplantation.
March 2003, Vol. 93, No. 3  SAMJ
SAMJ FORUM
Therapeutic interventions
Therapeutic interventions are based on this biochemical
background. Thus, there is a graded hazard for developing
atherosclerosis as plasma levels increase. This is an
independent factor equivalent to smoking and
hyperlipidaemia, in which a 5 µM increment, even in the
normal range, increases the risk between 60% and 80%
simultaneously targeting cerebral, peripheral and coronary
vasculature.3
Although pathophysiology is clear, controversy inexplicably
persists regarding treatment. Perhaps this is because, for
primary prevention, proof of benefit is not yet sufficient to
justify worldwide supplementation although preliminary
results are expected to reach statistical significance within 3
years.5 Quite different is the specific use of these vitamins to
avoid secondary complications. Thus, in
hyperhomocysteinaemic individuals, who have had an
occlusive episode, doses of cobalamin, folate and pyridoxine to
reduce the levels to the low-normal range is rational. Studies in
first-degree relatives are also quite appropriate and protection
with replacement therapy should be offered to such people
with raised values.1
Conclusions
Conclusions are threefold and quite clear. Rationally it is
recognised that local authority or government need to add at
least folate to some widely consumed food staple. Secondly, a
documented or arterial venous event, in the patient with
elevations in plasma level of this amino acid — especially
when other risk factors are also present — should receive this
quite specific form of treatment that differs in no way
conceptually from pharmacological lowering of blood pressure
or management of hyperglycaemia. Thirdly, close family
members who may not yet have had arterial or venous
thromboembolism but are similarly affected and particularly
when defects in naturally occurring anticoagulant mechanisms
are present, justify equivalent consideration. This is a
compelling argument that needs to be widely acknowledged
and responded to by doctors and nurses as well as third party
payers in South Africa — as it is elsewhere in the world.
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Population studies of coronary vascular disease such as the
Framingham study have identified cigarette smoking,
hypertension, diabetes mellitus, age, raised total cholesterol,
and low high-density lipoprotein (HDL) cholesterol as major
and independent risk factors for coronary heart disease
(CHD).1 These traditional risk factors may, however, be
insufficient to account for all cases of CHD and they do not
adequately explain the large differences in CHD rates between
populations.2 Novel risk factors such as homocysteine have
therefore gained popularity as potential independent risk
factors for CHD.3
Background
The hypothesis that homocysteine may be causally related to
thromboembolic disease stems from the observation that young
adults with the rare autosomal recessive disease of congenital
homocysteinuria die prematurely of atherosclerosis and
thrombosis. These individuals have extremely high plasma
levels of homocysteine and are generally treated with
methionine/cysteine-restricted diets and some sort of vitamin
B supplementation, depending on the specific underlying
enzymatic defect. Homocysteine is an amino acid generated in
the metabolism of dietary methionine. The latter is derived
exclusively from animal protein. Homocysteine undergoes
metabolism either by remethylation or transsulphuration.
Genetically determined enzyme dysfunctions (e.g.
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heterozygous cystathionine synthase deficiency), as well as
substrate and co-factor abnormalities, including folate, vitamin
B6 and vitamin B12 deficiency, may lead to elevated
homocysteine levels. Furthermore, methionine-rich diets,
excessive coffee consumption, high alcohol intake, smoking,
and lack of physical activity have been associated with high
serum concentrations.3 The prevalence of
hyperhomocysteinaemia in the general population has been
estimated to be between 5% and 10%, and as high as 30 - 40%
in the elderly population. 4 Considering the multiple genetic
and environmental factors that can influence homocysteine
levels, it is not surprising that such figures vary
geographically.5 The prevalence in various population groups
in South Africa is unknown.
The evidence
Over the past 30 years there has been an exponential increase
in publications relating to the association between raised
homocysteine levels and occlusive vascular disease. Various
reviewers of the subject have concluded that elevated
homocysteine is an independent risk factor for vascular disease
in coronary, cerebral and/or peripheral blood vessels.3,4,6 The
initial evidence supporting such a theory came from cross-
sectional and retrospective case-control studies such as the one
by Clarke et al.7 Subsequent prospective population-based
cohort and nested case-control studies supported such
findings. Nevertheless, results have not been consistent. Some
studies have indicated a continuous dose-response relationship
between increasing homocysteine concentrations and CHD
events,8,9 whereas others have suggested a threshold effect. 5,10
The US Physicians Study10 demonstrated a positive association
in the top 5% of the homocysteine distribution when compared
with the bottom 90%. It is interesting that these findings could
not be reproduced when the same cohort was followed beyond
5 years.11
To add to the confusion, other large population-based
prospective cohort studies have failed to show an independent
association.12-14 The most recent is a 10-year follow-up of the
Caerphilly cohort in the UK. 15 This was a nested case-control
study comparing homocysteine levels in 312 men (of an
original cohort of 2 290) who developed acute myocardial
infarction or death, with 1 248 randomly selected, age
frequency matched controls. Although geometric mean
homocysteine concentrations were slightly higher in cases than
controls, this did not reach statistical significance (12.2 µmol/l,
95% CI: 11.8 - 12.6 versus 11.8 µmol/l, 95% CI: 11.3 - 12.5, 
p = 0.09). Also, comparing the top 5% of the homocysteine
concentration with the remaining 95%, the adjusted odds ratio
of CHD was 1.05 (95% CI: 0.56 - 1.95, p = 0.9). A linear
association of homocysteine levels and cardiovascular
endpoints was observed, but this disappeared when controlled
for confounding variables such as smoking, obesity and
physical activity.
Hence, although homocysteine appears to be positively
associated with vascular events, it remains to be seen whether
it is an independent, and furthermore, causal risk factor for
thromboembolic disease. Elevated levels of plasma
homocysteine have been associated with major components of
the cardiovascular risk profile, including male gender, old age,
smoking, hypertension, hyperlipidaemia and a sedentary
lifestyle.16 They are also increased with renal and hepatic
impairment. It may be that high levels of homocysteine are a
result of, rather than the cause of, active underlying vascular
disease and positive results in short-term follow-up studies
may reflect prevalent subclinical vascular disease. Such reverse
causation has been suggested to occur in studies of another
putative vascular risk factor, lipoprotein(a).17 It may also be that
hyperhomocysteinaemia is only associated with an increased
risk at very high levels and/or in young people, which may be
indicative of genetic enzyme defects. A stronger association
between serum homocysteine level and ischaemic heart disease
at younger rather than older ages has been proposed.9
Regarding specific therapy for hyperhomocysteinaemia,
various studies have demonstrated a lowering in homocysteine
levels with folate and vitamin B therapy. According to a meta-
analysis, 0.5 - 5 mg of folate reduces homocysteine levels by
~25%, whereas 0.5 mg of vitamin B12 produces an additional
reduction of 7%. Vitamin B6 (mean 16.5 mg) did not have any
significant effect.18 Nevertheless, the latter has been proposed
as offering independent cardiovascular protection, that appears
to be separate to any effect on homocysteine levels.12 However,
no results of prospective randomised controlled trials are
available as yet to establish the effects of lowering
homocysteine on cardiovascular outcomes, or to ascertain the
effect of folate and vitamin B6 supplementation on such events.
Recommendations
Until such time as there is a better understanding of the
relationship between serum homocysteine levels, vascular
events and folate/vitamin B6/vitamin B12 levels and
supplementation, it is premature to advocate screening and
intervention programmes for elevated homocysteine levels.
Such practice should be confined to a research setting. This is
in agreement with the conclusions by the Canadian task force
on preventive health care which conducted an extensive
literature review of English-language publications between
1996 and 1999.4 Adherence to recommended daily allowance of
dietary sources of folate and vitamins B 12 and B6 should,
however, be encouraged and coffee consumption should be
kept low.3 The usual recommendations for a cardioprotective
lifestyle must be strongly advocated. Smoking cessation, ample
physical activity, moderate intake of animal protein, high
consumption of fresh plant produce and avoidance of excessive
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alcohol should not only have a beneficial effect on
homocysteine levels, but most have long been accepted as
offering a benefit to patients with regard to atherosclerotic
disease prophylaxis. Innovative ways of promoting such a
lifestyle need to be found. Accepting the difficulty regarding
the latter, the hopeful enthusiasm for yet another ‘pill’ and
widespread vitamin food fortification programmes in an effort
to reduce vascular occlusive disease can be easily understood.
Doctors in the desperate situation of treating patients with
accelerated premature atherosclerotic disease in the absence of
accepted risk factors or other treatable causes cannot be
criticised for prescribing vitamin B complexes. This
intervention is relatively cheap, in most likelihood it is safe and
it may give the patient the benefit of the doubt of any potential
therapeutic benefit. From a health policy and health funding
perspective, however, more data are required before resources
should be allocated towards the screening and intervention of
hyperhomocysteinaemia.
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The first adult case of HIV/AIDS in Malawi was identified in
April 1985,1,2 with the first paediatric case in January 1986.3
From that time to 1997, at least 10% of the general population
and 15% of the 15 - 49-year age group were infected.4,5 Up to
30% of women attending prenatal care at the Queen Elizabeth
Central Hospital, Blantyre, are HIV-infected.6,7 HIV/AIDS has
been associated with a rise in the number of orphans, now
estimated at between 400 000 and 1 000 000 as no reliable data
are currently available. The maternal mortality ratio, which had
been estimated at about 620 deaths per 100 000 live births in
the 1992 Demographic and Health Survey (MDHS),8 has now
risen to 1 120/100 000, 9 due inter alia to the HIV pandemic. Up
to 70% of admissions in the medical wards of Blantyre and
Lilongwe are HIV/AIDS-related and tuberculosis (TB) has
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